

**Anti-CD19 Reference Antibody (Loncastuximab)
Recombinant Antibody
Catalog # APR10085****Specification**

Anti-CD19 Reference Antibody (Loncastuximab) - Product Information

| | |
|-------------------|------------------------|
| Application | FC, E, FTA |
| Primary Accession | P15391 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 144.46 KDa |

Anti-CD19 Reference Antibody (Loncastuximab) - Additional Information**Target/Specificity**
CD19**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-CD19 Reference Antibody (Loncastuximab) - Protein Information****Name** CD19**Function**
Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes (PubMed:29523808). Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens (PubMed:1373518, PubMed:16672701, PubMed:2463100). Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores (PubMed:12387743, PubMed:16672701, PubMed:9317126, PubMed:9382888). Is not required

for early steps during B cell differentiation in the blood marrow (PubMed:9317126). Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges (PubMed:1373518, PubMed:2463100). Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge (PubMed:12387743, PubMed:16672701, PubMed:9317126).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Membrane raft
{ECO:0000250|UniProtKB:P25918}; Single-pass type I membrane protein
{ECO:0000250|UniProtKB:P25918}

Tissue Location


Detected on marginal zone and germinal center B cells in lymph nodes (PubMed:2463100).
Detected on blood B cells (at protein level) (PubMed:16672701, PubMed:2463100)

Anti-CD19 Reference Antibody (Loncastuximab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD19 Reference Antibody (Loncastuximab) - Images



Anti-CD19 Reference Antibody (Loncastuximab) on SDS-PAGE under reducing (R) condition. The

gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-CD19 Reference Antibody (Loncastuximab) is more than 100% ,determined by SEC-HPLC.